Tradestie Institutional Equity Comparison Engine

INSM vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while INSM counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, INSM trades at N/M Forward P/E with -41.7% operating margin (+268.4% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, INSM sits in CONSOLIDATION (37th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
INSM N/M vs MRNA 23.0x Fwd P/E
Growth & Margin Winner INSM
Op Margin -41.7% vs -80.8% ยท YoY +268.4% vs +29.2%
Momentum & Technical Winner MRNA
1Y -30.6% vs +706.5% ยท 52W Pos 42% vs 67%
Options & Structure Winner INSM
CONSOLIDATION (37th %ile IV) vs CONSOLIDATION (52nd %ile IV)
INSM NASDAQ
Insmed, Inc.
Pharmaceutical Preparations
$141.33
-2.17% 1D
Market Cap $31.7B
1M Return +48.67%
1Y Return -30.57%
Forward P/E N/M
Unified AI Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 69.0 Mom 40.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: INSM -30.57% MRNA +706.45% Spread: +737.02 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period INSM Revenue MRNA Revenue INSM Op. Margin MRNA Op. Margin Margin Edge
FY2018 $10M $140M -3124.9% -306.0% MRNA
FY2019 $140M $60M -172.4% -906.8% INSM
FY2020 $160M $800M -161.3% -95.0% MRNA
FY2021 $190M $18.5B -199.0% 72.0% MRNA
FY2022 $250M $19.3B -186.4% 48.9% MRNA
FY2023 $310M $6.85B -232.5% -61.9% MRNA
FY2024 $360M $3.24B -241.5% -121.9% MRNA
FY2025 $610M $1.94B -205.6% -158.1% MRNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: INSM (3) vs MRNA (7)
Institutional Metric INSM MRNA Criterion Row Winner
Market Capitalization Scale $31.7B $80.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 106.4x 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth +268.4% +29.2% Higher Growth INSM
Operating Margin (TTM) Profitability -41.7% -80.8% Higher Margin INSM
Net Profit Margin Profitability -39.9% -110.5% Higher Margin INSM
Return on Equity (ROE) Capital Efficiency -72.5% -34.5% Higher ROE MRNA
52-Week Range Position Momentum 42% ($90โ€“$213) 67% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 0.37ฮฒ ยท 91% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 39.6 / 100 (SELL) 40.3 / 100 (SELL) Higher Composite MRNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full INSM vs MRNA Buy Guide
INSM CONSOLIDATION
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live INSM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither INSM nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.